Stock Markets News
Stock and Market News

Spotlite360 Technologies Inc, BioHarvest Sciences Inc, Kainantu Resources Ltd,

A glance at some of the day’s highlights from the Proactive Investors US and Canada newswires

Inc (), the logistics technologies developer, debuted its shares on the Canadian Securities Exchange on June 15. Shares of the Denver- and Vancouver-based company are trading under the ticker symbol ‘LITE.’ The listing follows Spotlite360’s recent acquisition of Captios LLC, a supply chain innovator, which is now a wholly owned subsidiary of the company.

BioHarvest Sciences Inc () () (FRA:8MV) has said that VINIA, its red grape cell functional food, is the “only dietary supplement in the US market” which reduces the endothelin 1 (ET1) enzyme, and increases the nitric oxide (NO) molecules, in order to “increase the dilation of arteries and thereby improve blood flow.” The Vancouver-based company explained that the presence of ET1 constricts a blood vessel, whereas the presence of nitric oxide dilates it. As a result of its “double-action effect,” demonstrated by the Flow Mediated Dilatation measurements in a double-blinded placebo-controlled clinical trial and in an in-vitro study, whose results were both published, VINIA is “uniquely positioned to combat the aging process caused by a reduction in blood flow,” noted the company.

() (FRA:6J0) said it executed definitive agreements to gain control of the May River project in the world-renowned copper and gold district of Frieda River, Papua New Guinea (PNG). The gold miner entered into two separate definitive purchase agreements with ASX-listed Niuminco () and Hardrock, a private company. The deals will see Kainantu gain control of the highly prospective copper and gold mineral concessions, known as the May River project through the acquisition of two holding companies. The area consolidates three adjoining tenements and is less than 15 kilometers (km) away from the PanAust () owned world-renowned Frieda River project.

KushCo Holdings Inc () has said it expects to generate preliminary and unaudited fiscal third quarter 2021 revenue of between $27.5 million and $28.0 million, a 21%-26% year-over-year gain, driven primarily by an increase in sales to the company’s top 25 customers that include leading multi-state operators (MSOs), licensed producers (LPs), and brands. The company noted that revenue from its top 25 customers is expected to increase by more than 60% to at least $20.5 million in 3Q. “Not only are our sales to these customers continuing to grow, but the quality of the customers we are serving is also continuing to improve, as we have a much stronger book of the right customers than we did a year ago,” KushCo Holdings CEO Nick Kovacevich said in a statement.

Nextleaf Solutions Ltd () () has announced the launch of a Specialty Molecules Division to focus on the development and commercialization of novel psychoactive compounds. The company said the division is supported by its existing intellectual property (IP) portfolio, including the manufacturing of CBD-O-acetate and the recently announced US patent for the synthesis of THC-O-acetate. “The purpose of this new division is to leverage Nextleaf’s existing intellectual property and delivery technology to develop IP-protected therapeutic products from novel molecules,” said Nextleaf CEO Paul Pedersen in a statement.

BioSig Technologies Inc () has announced that it will present an exhibit at the Heart Rhythm 2021 convention, held July 28-31 at the Boston Convention and Exhibition Center. The company’s executive leadership, and clinical, commercial and engineering teams will host a series of presentations at booth 849 that will showcase the latest clinical data and demonstrate the newest software features of its PURE EP System, the non-invasive Class 2 device that aims to drive procedural efficiency and efficacy in electrophysiology. BioSig will also host a series of invitation-only events that will feature physician user presentations. BioSig completed enrollments in its clinical trial in April 2021. During the 51-patient trial, the PURE EP System was used in all types of cardiac arrhythmia cases. Atrial fibrillation, the most common arrhythmia type, accounted for more than 40% of enrollments.

Chesapeake Financial Shares, Inc. (), the parent company of both Chesapeake Bank and Chesapeake Wealth Management has confirmed that its second-quarter dividend of $0.130 per share is payable on or before June 15, 2021. 

() () (FRA:4XT) said it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. “With both its North American GMP mescaline synthesis program and German-based psilocybin biotechnology production…

Read More: Spotlite360 Technologies Inc, BioHarvest Sciences Inc, Kainantu Resources Ltd,

Notify of
Inline Feedbacks
View all comments

Get more stuff like this
in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.